Triple-negative breast cancer (TNBC) represents 10-20% of breast cancers and is characterized by the absence of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression, leaving cytotoxic chemotherapy as the main systemic treatment. Here, PGR is linked to triple-negative breast carcinoma.